Matches in Wikidata for { <http://www.wikidata.org/entity/Q96143500> ?p ?o ?g. }
Showing items 1 to 38 of
38
with 100 items per page.
- Q96143500 description "clinical trial" @default.
- Q96143500 description "ensayo clínico" @default.
- Q96143500 description "ensayu clínicu" @default.
- Q96143500 description "klinisch onderzoek" @default.
- Q96143500 description "клінічне випробування" @default.
- Q96143500 description "կլինիկական փորձարկում" @default.
- Q96143500 description "临床试验" @default.
- Q96143500 name "First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors" @default.
- Q96143500 name "First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors" @default.
- Q96143500 type Item @default.
- Q96143500 label "First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors" @default.
- Q96143500 label "First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors" @default.
- Q96143500 prefLabel "First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors" @default.
- Q96143500 prefLabel "First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors" @default.
- Q96143500 P1132 Q96143500-C42BBDBA-FB12-48A8-BE07-77E1B1053A02 @default.
- Q96143500 P1476 Q96143500-997B8E3B-FDA5-4E6B-8894-6247E1FC59AA @default.
- Q96143500 P17 Q96143500-5506B8C6-1EFE-46A6-AF42-5EFA7A46D60F @default.
- Q96143500 P2899 Q96143500-8D58DCD6-C0EF-4E47-AE48-357DE325FED9 @default.
- Q96143500 P3098 Q96143500-92744EF3-A3D5-40D7-9602-0AC83AFE23BA @default.
- Q96143500 P31 Q96143500-75094747-32D0-4F6C-970F-ECE3110D6977 @default.
- Q96143500 P580 Q96143500-8D81FCC8-5B20-4983-A4A6-E3A9545F8228 @default.
- Q96143500 P582 Q96143500-AFAC905A-60B0-42FD-90E5-67C0A287F734 @default.
- Q96143500 P6099 Q96143500-97DBB19D-4D02-4DD6-B175-2186650F22F1 @default.
- Q96143500 P8005 Q96143500-CE645A15-FD51-4FCD-9E5D-198AA62CC65E @default.
- Q96143500 P8363 Q96143500-780287F2-F47D-4259-BF0D-057A134F6E63 @default.
- Q96143500 P921 Q96143500-CB8B9FCF-C0CE-4416-B404-261B884F34EC @default.
- Q96143500 P1132 "+43" @default.
- Q96143500 P1476 "A Phase 1, Multi-center, Open Label First-in-Human Study With ABBV-CLS-579 Alone and in Combination With Anti-PD-1 in Subjects With Locally Advanced or Metastatic Tumors" @default.
- Q96143500 P17 Q30 @default.
- Q96143500 P2899 "+18" @default.
- Q96143500 P3098 "NCT04417465" @default.
- Q96143500 P31 Q30612 @default.
- Q96143500 P580 "2020-06-03T00:00:00Z" @default.
- Q96143500 P582 "2023-04-06T00:00:00Z" @default.
- Q96143500 P6099 Q5452194 @default.
- Q96143500 P8005 Q76649708 @default.
- Q96143500 P8363 Q78089383 @default.
- Q96143500 P921 Q12078 @default.